Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

[⁸⁹Zr]Zr-DFO-girentuximab and [¹⁸F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Clin Cancer Res (2023) 29 (3): 592–601.

https://doi.org/10.1158/1078-0432.CCR-22-0921

Published: 01 February 2023

View article titled, [<sup>89</sup>Zr]Zr-DFO-girentuximab and [<sup>18</sup>F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Includes: Supplementary data

Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Clin Cancer Res (2022) 28 (7): 1402–1411.

https://doi.org/10.1158/1078-0432.CCR-21-3752

Published: 01 April 2022

View article titled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Includes: Supplementary data

Journal Articles

DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas

Marije E. Weidema, Ellen van de Geer, Christian Koelsche, Ingrid M.E. Desar, Patrick Kemmeren, Melissa H.S. Hillebrandt-Roeffen, Vincent K.Y. Ho, Winette T.A. van der Graaf, Yvonne M.H. Versleijen-Jonkers, Andreas von Deimling, Uta E. Flucke

Clin Cancer Res (2020) 26 (1): 93–100.

https://doi.org/10.1158/1078-0432.CCR-19-2180

Published: 03 January 2020

View article titled, DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas

Includes: Supplementary data

Journal Articles

Abstract A36: ImmunoSPECT and ImmunoPET imaging of IGF-1R expression in a model for triple negative breast cancer

Sandra Heskamp, Otto C. Boerman, Wim J.G. Oyen, Janneke D.M. Molkenboer-Kuenen, Winette T.A. van der Graaf, Hanneke W.M. van Laarhoven

Clin Cancer Res (2010) 16 (7_Supplement): A36.

https://doi.org/10.1158/1078-0432.TCME10-A36

Published: 02 February 2016

View article titled, Abstract A36: ImmunoSPECT and ImmunoPET imaging of IGF-1R expression in a model for triple negative breast cancer

Journal Articles

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Melanie M. Hagleitner, Marieke J.H. Coenen, Hans Gelderblom, Remco R. Makkinje, Hanneke I. Vos, Eveline S.J.M. de Bont, Winette T.A. van der Graaf, H.W. Bart Schreuder, Uta Flucke, Frank N. van Leeuwen, Peter M. Hoogerbrugge, Henk-Jan Guchelaar, Dunja M.W.M te Loo

Clin Cancer Res (2015) 21 (15): 3436–3441.

https://doi.org/10.1158/1078-0432.CCR-14-2638

Published: 02 August 2015

View article titled, A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Includes: Supplementary data

Journal Articles

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Karel Eechoute, Martin N. Fransson, An K. Reyners, Floris A. de Jong, Alex Sparreboom, Winette T.A. van der Graaf, Lena E. Friberg, Gaia Schiavon, Erik A.C. Wiemer, Jaap Verweij, Walter J. Loos, Ron H.J. Mathijssen, Ugo De Giorgi

Clin Cancer Res (2012) 18 (20): 5780–5787.

https://doi.org/10.1158/1078-0432.CCR-12-0490

Published: 14 October 2012

View article titled, A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Includes: Supplementary data

Journal Articles

Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507

Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Addy C.M. van de Luijtgaarden, Janneke D.M. Molkenboer-Kuenen, Sandra Heskamp, Melissa H.S. Roeffen, Hanneke W.M. van Laarhoven, Peter J. Houghton, Wim J.G. Oyen, Otto C. Boerman, Winette T.A. van der Graaf

Clin Cancer Res (2011) 17 (24): 7693–7703.

https://doi.org/10.1158/1078-0432.CCR-11-1488

Published: 18 December 2011

View article titled, Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507

Includes: Supplementary data

NARROW

[⁸⁹Zr]Zr-DFO-girentuximab and [¹⁸F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas

Abstract A36: ImmunoSPECT and ImmunoPET imaging of IGF-1R expression in a model for triple negative breast cancer

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507

Email alerts

AACR Journals

[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas

Abstract A36: ImmunoSPECT and ImmunoPET imaging of IGF-1R expression in a model for triple negative breast cancer

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

[⁸⁹Zr]Zr-DFO-girentuximab and [¹⁸F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma